Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have earned an average recommendation of “Hold” from the fourteen brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $26.36.
NTLA has been the topic of several analyst reports. Robert W. Baird initiated coverage on shares of Intellia Therapeutics in a research report on Monday, July 8th. They set an “outperform” rating and a $23.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $57.50 target price on shares of Intellia Therapeutics in a research report on Tuesday, May 28th. BidaskClub lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. Roth Capital started coverage on Intellia Therapeutics in a research report on Monday, June 10th. They issued a “neutral” rating and a $16.00 target price on the stock. Finally, Zacks Investment Research lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th.
Shares of NTLA stock traded down $0.21 during trading on Wednesday, hitting $13.63. 402,161 shares of the stock traded hands, compared to its average volume of 476,648. The firm has a market capitalization of $676.43 million, a P/E ratio of -6.88 and a beta of 2.71. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.99 and a quick ratio of 7.99. The firm’s fifty day moving average price is $16.58 and its 200-day moving average price is $16.02. Intellia Therapeutics has a 52-week low of $11.03 and a 52-week high of $32.95.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Benjamin Edwards Inc. raised its position in Intellia Therapeutics by 60.9% in the second quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock valued at $28,000 after purchasing an additional 640 shares during the period. Tortoise Investment Management LLC grew its stake in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock worth $34,000 after acquiring an additional 1,000 shares in the last quarter. Quantamental Technologies LLC grew its stake in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock worth $56,000 after acquiring an additional 3,043 shares in the last quarter. Bank of Montreal Can grew its stake in shares of Intellia Therapeutics by 406.5% in the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after acquiring an additional 3,069 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. acquired a new position in shares of Intellia Therapeutics in the second quarter worth $64,000. 80.96% of the stock is currently owned by institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Featured Article: Why Net Income is Important to Investors
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.